Marrow stromal cells differentiate into vasculature after allogeneic transplantation into ischemic myocardium

Yifu Zhou, Suna Wang, Zuxi Yu, Robert F. Hoyt, Xuan Qu, Keith A. Horvath

Research output: Contribution to journalArticle

Abstract

Background: Marrow stromal cells (MSCs) are reportedly able to improve ventricular function after myocardial infarction through the paracrine effect or regenerating myocytes. However, the evidence to prove that is scant. In this animal study, we employed MSCs isolated from transgenic pigs designed to express enhanced green fluorescent proteins as the donor to study the fate of the cells after allogeneic transplantation. Methods: Green MSCs prepared from transgenic pigs were allogeneically transplanted into chronic ischemic myocardium of 8 Yorkshire pigs by direct intramyocardial injection (total 1.2 × 10 8 cells in 2.5 mL saline, with 25 injection sites). Cohorts of 2 animals were sacrificed at 1, 2, 4, and 6 weeks, and 3 months after injection to study the fate of the injected cells. Results: Allogeneic injection of the green MSCs is safe; no observable side effects or signs of graft versus host disease were observed. By 4′,6-diamidino-2-phenylindole (DAPI) counterstained frozen sections, the green cells were found migrating from the injected area into deeper layers of myocardium over the course of 1 to 6 weeks. By immunofluorescent staining, the green cells were associated with smooth muscle actin or von Willebrand factor positive cells, suggesting that the transplanted cells were contributing to the formation of new vessels. We found no evidence that these cells were associated with the new generation of cardiac myocytes. Three months after injection, clusters of MSCs still can be found in the middle layer of ischemic myocardium; however, no unlimited cell growth was found. Conclusions: Allogeneic transplantation of green MSCs can be safely used to elucidate the mechanisms of cell-based therapy. The benefits of this therapy appear mainly due to the angiogenesis, not the regeneration, of cardiac myocytes.

Original languageEnglish (US)
Pages (from-to)1206-1212
Number of pages7
JournalAnnals of Thoracic Surgery
Volume91
Issue number4
DOIs
StatePublished - Apr 2011
Externally publishedYes

Fingerprint

Homologous Transplantation
Stromal Cells
Myocardium
Bone Marrow
Injections
Swine
Cardiac Myocytes
Ventricular Function
von Willebrand Factor
Frozen Sections
Graft vs Host Disease
Cell- and Tissue-Based Therapy
Muscle Cells
Smooth Muscle
Actins
Regeneration
Myocardial Infarction
Staining and Labeling
Growth

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Marrow stromal cells differentiate into vasculature after allogeneic transplantation into ischemic myocardium. / Zhou, Yifu; Wang, Suna; Yu, Zuxi; Hoyt, Robert F.; Qu, Xuan; Horvath, Keith A.

In: Annals of Thoracic Surgery, Vol. 91, No. 4, 04.2011, p. 1206-1212.

Research output: Contribution to journalArticle

Zhou, Yifu ; Wang, Suna ; Yu, Zuxi ; Hoyt, Robert F. ; Qu, Xuan ; Horvath, Keith A. / Marrow stromal cells differentiate into vasculature after allogeneic transplantation into ischemic myocardium. In: Annals of Thoracic Surgery. 2011 ; Vol. 91, No. 4. pp. 1206-1212.
@article{298c361868cd4a2caaa3f401005ed960,
title = "Marrow stromal cells differentiate into vasculature after allogeneic transplantation into ischemic myocardium",
abstract = "Background: Marrow stromal cells (MSCs) are reportedly able to improve ventricular function after myocardial infarction through the paracrine effect or regenerating myocytes. However, the evidence to prove that is scant. In this animal study, we employed MSCs isolated from transgenic pigs designed to express enhanced green fluorescent proteins as the donor to study the fate of the cells after allogeneic transplantation. Methods: Green MSCs prepared from transgenic pigs were allogeneically transplanted into chronic ischemic myocardium of 8 Yorkshire pigs by direct intramyocardial injection (total 1.2 × 10 8 cells in 2.5 mL saline, with 25 injection sites). Cohorts of 2 animals were sacrificed at 1, 2, 4, and 6 weeks, and 3 months after injection to study the fate of the injected cells. Results: Allogeneic injection of the green MSCs is safe; no observable side effects or signs of graft versus host disease were observed. By 4′,6-diamidino-2-phenylindole (DAPI) counterstained frozen sections, the green cells were found migrating from the injected area into deeper layers of myocardium over the course of 1 to 6 weeks. By immunofluorescent staining, the green cells were associated with smooth muscle actin or von Willebrand factor positive cells, suggesting that the transplanted cells were contributing to the formation of new vessels. We found no evidence that these cells were associated with the new generation of cardiac myocytes. Three months after injection, clusters of MSCs still can be found in the middle layer of ischemic myocardium; however, no unlimited cell growth was found. Conclusions: Allogeneic transplantation of green MSCs can be safely used to elucidate the mechanisms of cell-based therapy. The benefits of this therapy appear mainly due to the angiogenesis, not the regeneration, of cardiac myocytes.",
author = "Yifu Zhou and Suna Wang and Zuxi Yu and Hoyt, {Robert F.} and Xuan Qu and Horvath, {Keith A.}",
year = "2011",
month = "4",
doi = "10.1016/j.athoracsur.2011.01.021",
language = "English (US)",
volume = "91",
pages = "1206--1212",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Marrow stromal cells differentiate into vasculature after allogeneic transplantation into ischemic myocardium

AU - Zhou, Yifu

AU - Wang, Suna

AU - Yu, Zuxi

AU - Hoyt, Robert F.

AU - Qu, Xuan

AU - Horvath, Keith A.

PY - 2011/4

Y1 - 2011/4

N2 - Background: Marrow stromal cells (MSCs) are reportedly able to improve ventricular function after myocardial infarction through the paracrine effect or regenerating myocytes. However, the evidence to prove that is scant. In this animal study, we employed MSCs isolated from transgenic pigs designed to express enhanced green fluorescent proteins as the donor to study the fate of the cells after allogeneic transplantation. Methods: Green MSCs prepared from transgenic pigs were allogeneically transplanted into chronic ischemic myocardium of 8 Yorkshire pigs by direct intramyocardial injection (total 1.2 × 10 8 cells in 2.5 mL saline, with 25 injection sites). Cohorts of 2 animals were sacrificed at 1, 2, 4, and 6 weeks, and 3 months after injection to study the fate of the injected cells. Results: Allogeneic injection of the green MSCs is safe; no observable side effects or signs of graft versus host disease were observed. By 4′,6-diamidino-2-phenylindole (DAPI) counterstained frozen sections, the green cells were found migrating from the injected area into deeper layers of myocardium over the course of 1 to 6 weeks. By immunofluorescent staining, the green cells were associated with smooth muscle actin or von Willebrand factor positive cells, suggesting that the transplanted cells were contributing to the formation of new vessels. We found no evidence that these cells were associated with the new generation of cardiac myocytes. Three months after injection, clusters of MSCs still can be found in the middle layer of ischemic myocardium; however, no unlimited cell growth was found. Conclusions: Allogeneic transplantation of green MSCs can be safely used to elucidate the mechanisms of cell-based therapy. The benefits of this therapy appear mainly due to the angiogenesis, not the regeneration, of cardiac myocytes.

AB - Background: Marrow stromal cells (MSCs) are reportedly able to improve ventricular function after myocardial infarction through the paracrine effect or regenerating myocytes. However, the evidence to prove that is scant. In this animal study, we employed MSCs isolated from transgenic pigs designed to express enhanced green fluorescent proteins as the donor to study the fate of the cells after allogeneic transplantation. Methods: Green MSCs prepared from transgenic pigs were allogeneically transplanted into chronic ischemic myocardium of 8 Yorkshire pigs by direct intramyocardial injection (total 1.2 × 10 8 cells in 2.5 mL saline, with 25 injection sites). Cohorts of 2 animals were sacrificed at 1, 2, 4, and 6 weeks, and 3 months after injection to study the fate of the injected cells. Results: Allogeneic injection of the green MSCs is safe; no observable side effects or signs of graft versus host disease were observed. By 4′,6-diamidino-2-phenylindole (DAPI) counterstained frozen sections, the green cells were found migrating from the injected area into deeper layers of myocardium over the course of 1 to 6 weeks. By immunofluorescent staining, the green cells were associated with smooth muscle actin or von Willebrand factor positive cells, suggesting that the transplanted cells were contributing to the formation of new vessels. We found no evidence that these cells were associated with the new generation of cardiac myocytes. Three months after injection, clusters of MSCs still can be found in the middle layer of ischemic myocardium; however, no unlimited cell growth was found. Conclusions: Allogeneic transplantation of green MSCs can be safely used to elucidate the mechanisms of cell-based therapy. The benefits of this therapy appear mainly due to the angiogenesis, not the regeneration, of cardiac myocytes.

UR - http://www.scopus.com/inward/record.url?scp=79953102569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953102569&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2011.01.021

DO - 10.1016/j.athoracsur.2011.01.021

M3 - Article

VL - 91

SP - 1206

EP - 1212

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 4

ER -